Related Experiment Video
Updated: Aug 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells
Shalini Murthy1, Irina U Agoulnik, Nancy L Weigel
1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas77030, USA.
Background:
1,25(OH)2D3 inhibits the growth of prostate cancer cells; previous reports suggest that 1,25(OH)2D3 actions in LNCaP prostate cancer cells are androgen dependent. This is due in part to the observation that the androgen receptor (AR) antagonist, Casodex, modestly inhibits LNCaP cell growth, but reduces the greater growth inhibition induced by 1,25(OH)2D3 to the level of Casodex alone. Because androgen ablation therapy is used for metastatic prostate cancer, we sought to better characterize this androgen dependence.
Methods:
We have assessed the requirement for endogenous androgens in 1,25(OH)2D3 mediated growth inhibition of AR+ prostate cancer cell lines. We have also sought the mechanism for anti-androgen mediated reversal of 1,25(OH)2D3 dependent growth inhibition in LNCaP cells.
Results:
Although 1,25(OH)2D3 does not inhibit the growth of LNCaP cells grown in medium lacking androgens, we find that growth of androgen independent derivatives of LNCaP cells is inhibited by 1,25(OH)2D3. Despite this independence, Casodex treatment reduced the response of these cells to 1,25(OH)2D3 suggesting a unique function for Casodex-bound AR. Because Casodex does not directly inhibit the transcriptional activity of the vitamin D receptor (VDR) we sought a common primary target of VDR and AR action whose VDR dependent transcription could be repressed by Casodex. We report that AS3 (APRIN), a novel gene required for androgen dependent growth arrest, is a primary target for 1,25(OH)2D3 and androgens. Moreover, Casodex reduces induction of AS3 by 1,25(OH)2D3 suggesting that it is a candidate for the Casodex effect. Analysis of functional interactions between AR and VDR in other AR containing prostate cancer cells lines (PC-3 AR, LAPC-4, and 22Rv1) revealed that Casodex reversal was unique to LNCaP derived cells.
Conclusion:
Anti-androgen mediated reversal of 1,25(OH)2D3 dependent growth inhibition is limited to LNCaP derived prostate cancer cell lines. Moreover, the growth of androgen independent derivatives of LNCaP cells in medium depleted of androgens is strongly inhibited by 1,25D. Therefore, most forms of androgen ablation should not eliminate the utility of VDR agonist treatment in most prostate cancers.
Insights
Vitamin D3 inhibits prostate cancer cell growth, but this effect is partly reversed by anti-androgens in some cell lines. However, vitamin D3 remains effective against most prostate cancers, even with androgen ablation therapy.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- 1,25(OH)2D3 inhibits prostate cancer cell growth.
- Previous studies suggest 1,25(OH)2D3 actions in LNCaP cells are androgen-dependent.
- Anti-androgen therapy is used for metastatic prostate cancer.
Purpose of the Study:
- To assess the requirement for endogenous androgens in 1,25(OH)2D3-mediated growth inhibition of AR+ prostate cancer cell lines.
- To investigate the mechanism of anti-androgen reversal of 1,25(OH)2D3-dependent growth inhibition in LNCaP cells.
Main Methods:
- Assessed androgen requirement for 1,25(OH)2D3 growth inhibition in AR+ prostate cancer cell lines.
- Investigated mechanism of anti-androgen reversal of 1,25(OH)2D3-dependent growth inhibition.
- Analyzed AS3 (APRIN) gene as a potential common target.
Main Results:
- 1,25(OH)2D3 inhibited androgen-independent LNCaP cell derivatives, but Casodex reduced this response.
- AS3 (APRIN), a gene crucial for androgen-dependent growth arrest, is a primary target for both 1,25(OH)2D3 and androgens.
- Casodex reduced AS3 induction by 1,25(OH)2D3, suggesting a role in the observed effect.
- Casodex reversal of 1,25(OH)2D3 effects was unique to LNCaP-derived cells.
Conclusions:
- Anti-androgen reversal of 1,25(OH)2D3-dependent growth inhibition is specific to LNCaP-derived prostate cancer cell lines.
- 1,25(OH)2D3 strongly inhibits androgen-independent LNCaP cell derivatives.
- VDR agonist treatment is likely effective in most prostate cancers, irrespective of androgen ablation therapy.
More Related Videos
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
11:13Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Related Concept Videos
Internal Receptors
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin D3(cholecalciferol).